Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.

[1]  R. Giugliano,et al.  Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2018, Circulation.

[2]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[3]  9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[4]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[5]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[6]  R. Giugliano,et al.  The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. , 2016, European heart journal.

[7]  Jennifer G. Robinson,et al.  Determining When to Add Nonstatin Therapy: A Quantitative Approach. , 2016, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[9]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[10]  R. Giugliano,et al.  Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.

[11]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[12]  L. Kappelle,et al.  Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations , 2015, Diabetes Care.

[13]  Marc P. Bonaca,et al.  Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2°P-TIMI 50 Trial , 2015 .

[14]  R. Califf,et al.  Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. , 2014, American heart journal.

[15]  Deepak L. Bhatt,et al.  Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non–ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular quality and outcomes.

[16]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[17]  Deepak L. Bhatt,et al.  Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry , 2010, Vascular medicine.

[18]  Deepak L. Bhatt,et al.  Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. , 2009, European heart journal.

[19]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[20]  W. Howard.  Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. , 2007, Journal of vascular surgery.

[21]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.